Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rubesent is a branded generic hematinic combination developed by Avogadro, primarily indicated for the treatment and prevention of iron deficiency anemia and nutritional deficiencies. It is formulated as both an oral syrup and a tablet. The product contains **ferrous ascorbate**, a synthetic molecule of ascorbic acid and iron that offers high elemental iron bioavailability with reduced gastrointestinal irritation compared to traditional iron salts, and **folic acid** (Vitamin B9), which is essential for DNA synthesis and the maturation of red blood cells. Rubesent is commonly prescribed to support hematological health during pregnancy, lactation, and in patients with chronic blood loss or poor dietary intake.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rubesent.